Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475304 | 0.94 | HSD11B1 (0.34) | HSD11B1LMNAALDH1A1SMN1; SMN2NR1H2 | |
| SCHEMBL13475303 | 0.89 | NR1H2 (0.34) | HSD11B1LMNAALDH1A1SMN1; SMN2NR1H2 | |
| SCHEMBL13475305 | 0.88 | EPAS1 (0.35) | HSD11B1NR1H2NR1H3EPAS1PTGFR | |
| SCHEMBL13475213 | 0.87 | NR1H2 (0.42) | HSD11B1LMNAALDH1A1SMN1; SMN2NR1H2 | |
| SCHEMBL2788779 | 0.83 | MEN1 (0.41) | LMNAALDH1A1SMN1; SMN2METAP2PTGFR | |
| SCHEMBL13475208 | 0.78 | CA1 (0.42) | MEN1KMT2A | |
| SCHEMBL13475218 | 0.77 | PDK1 (0.45) | MEN1KMT2A | |
| SCHEMBL2789511 | 0.76 | MEN1 (0.43) | LMNAALDH1A1SMN1; SMN2PTGFRTSHR | |
| SCHEMBL13475315 | 0.76 | KMT2A (0.41) | LMNANR1H2NR1H3PTGFRMEN1 | |
| SCHEMBL13436115 | 0.76 | GCGR (0.38) | PTGFRSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | HSD11B1 66/4885LMNA 4278/4885ALDH1A1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.